VANDA PHARMACEUTICALS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.885 USD | -6.60% |
|
-3.91% | +16.35% |
| May. 27 | Global markets live: UBS, Tesla, Nvidia, Apple, Micron... |  |
| May. 24 | Vanda Pharmaceuticals rejects Future Pak's revised takeover offer | RE |
Financials (USD)
| Sales 2024 * | 194M | Sales 2025 * | 232M | Capitalization | 304M |
|---|---|---|---|---|---|
| Net income 2024 * | -3M | Net income 2025 * | -19M | EV / Sales 2024 * | 0.59 x |
| Net cash position 2024 * | 189M | Net Debt 2025 * | 65.1M | EV / Sales 2025 * | 1.59 x |
| P/E ratio 2024 * |
-87.2
x | P/E ratio 2025 * |
-15.8
x | Employees | 203 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vanda Pharmaceuticals Inc.
More recommendations
More press releases
More news
| 1 day | +6.52% | ||
| 1 week | -0.76% | ||
| Current month | +9.87% | ||
| 1 month | +13.20% | ||
| 3 months | +13.94% | ||
| 6 months | +46.91% | ||
| Current year | +23.93% |
1 week
4.88
5.23
1 month
4.625.95
Current year
3.466.03
1 year
3.306.76
3 years
3.3021.86
5 years
3.3021.86
10 years
3.3033.44
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 02-10-31 | |
Kevin Moran
DFI | Director of Finance/CFO | 40 | 12-11-30 |
Scott Howell
HRO | Human Resources Officer | - | 19-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Dugan
BRD | Director/Board Member | 82 | 05-11-30 |
| Chief Executive Officer | 64 | 02-10-31 | |
Stephen Mitchell
BRD | Director/Board Member | 72 | 20-02-13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.34% | 28 M€ | -1.64% | ||
| 0.22% | 25 M€ | -2.72% | - | |
| 0.05% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 4.905 | -6.21% | 795 915 |
| 24-05-24 | 5.23 | +6.52% | 896,861 |
| 24-05-23 | 4.91 | -4.47% | 847,738 |
| 24-05-22 | 5.14 | +0.59% | 701,194 |
| 24-05-21 | 5.11 | -3.04% | 770,126 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotes
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâs commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Calendar
2024-07-30
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
5.23
USD
Average target price
5.21
USD
Spread / Average Target
-0.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.93% | 304M | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -1.34% | 22.1B | |
| -8.21% | 18.34B | |
| -41.70% | 16.59B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- VNDA Stock
